Trial recruitment

Upcoming and ongoing clinical trials aim to expand an understanding of Kesimpta (ofatumumab), the Novartis therapy recently approved by the U.S. Food and Drug Administration (FDA) to treat relapsing forms of multiple sclerosis (MS). Kesimpta is an anti-CD20 monoclonal antibody, a type of treatment that is thought to work…

A $41,000 fellowship from the National Institutes of Health (NIH) aims to advance research into how changes in brain connectivity are related to the cognitive deficits seen in people with multiple sclerosis (MS). The Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship was granted to…

GeNeuro announced that a first multiple sclerosis (MS) patient has enrolled in its Phase 2 trial assessing the safety and effectiveness of temelimab in people whose disease is progressing in the absence of relapses. This trial, taking place at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm, had been postponed to reduce…

A first person has enrolled in Sanofi’s Phase 3 trial evaluating SAR442168, an oral BTK inhibitor intended to treat relapsing forms of multiple sclerosis (MS), Sanofi’s partner, Principia Biopharma, announced. “We are delighted that Sanofi has initiated … [this] trial in patients with relapsing MS,” Roy Hardiman, chief…

A study aiming to better understand falls and fall-related injuries in people with multiple sclerosis (MS) and other neurological disorders while self-isolating during the COVID-19 pandemic is recruiting participants. The online study, largely in the form of a questionnaire, is being carried out by the Motor Control Research…

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum post “I’ve Been Spoiled by My Clinical Trial,” published March 5. Share your…

Researchers at Vrije University Amsterdam in the Netherlands are inviting employed people with multiple sclerosis (MS) to take part in an online survey, in the form of three questionnaires spaced over two months, on their working life. This study will investigating potential connections between the perceived severity of MS symptoms, and…

In response to the COVID-19 pandemic, Atara Biotherapeutics has temporarily paused patient enrollment in the second and randomized part of its ongoing Phase 1 clinical trial investigating ATA188 in people with progressive forms of multiple sclerosis (MS). People treated in the first, open-label part of this trial, however,…

A planned Phase 2 clinical trial of a potential treatment for progressive multiple sclerosis has been postponed to keep hospital resources open to treat people with COVID-19 during the ongoing global outbreak, and to reduce the risk of exposure to MS patients, GeNeuro, the investigate therapy’s developer, announced. The…

The new year brings many changes, including the last year of my clinical trial. When I think about the past seven years, I am thankful for the opportunity to join the trial when I did and receive personal care that made fighting MS easier. It may sound crazy, but…

Mayzent Helps Regulate the Immune System in SPMS, Study Shows Mayzent (siponimod) is one of several disease-modifying treatments that target specific T-cells and B-cells involved in damage to the myelin that protects our nerves. This study reports a significant reduction in these rogue cells within a year of starting…

A new clinical trial is comparing the best available therapies to an experimental stem cell therapy to treat severe forms of relapsing multiple sclerosis (MS). At the moment, more than a dozen therapies have been approved by the U.S. Food and Drug Administration for the treatment of relapsing forms…

Pear Therapeutics announced that a first patient is being treated in Part 2 of its feasibility trial of Pear-006, a software application that, given along with a disease-modifying therapy, delivers cognitive behavioral therapy and other neurobehavioral approaches to ease depression in people with multiple sclerosis (MS). Pear-006, being developed…

A grant awarded recently by the National Institutes of Health (NIH) will fund research to explore how brain changes in multiple sclerosis (MS) patients affect mobility. The five-year grant (1R01NS109023-01A1), totaling $3.5 million, was awarded by the National Institute of Neurological Disorders and Stroke, part of…

The National Multiple Sclerosis Society awarded more than $339,000 to Clene Nanomedicine to support clinical tests into its lead candidate CNM-Au8 in treating multiple sclerosis (MS) by protecting nerve cells and restoring myelin. The grant was awarded under the National MS Society’s Fast Forward program, which aims…

Immunic Therapeutics announced that a Phase 2 clinical trial of IMU-838, its experimental oral therapy for relapsing-remitting multiple sclerosis (RRMS), is fully enrolled ahead of schedule. The trial, called EMPhASIS, also exceeded its target number of participants: Immunic set an initial recruitment goal of 195 patients by mid-2020, and enrolled 210…

A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses, or those whose disease is not active, MediciNova announced. Data from this single Phase 3 study may be used to request…

A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis (MS), has been dosed in a study taking place in The Netherlands, the company announced. T20K is an investigational…

Cyxone launched the first-in-human Phase 1 clinical trial assessing the effects of T20K, its new therapeutic candidate for the treatment of multiple sclerosis (MS), in healthy volunteers. The announcement came after the company received approval from the Dutch Ethics Committee and Central Commission on Research Involving Human…

A clinical trial based at the Cleveland Clinic and the University of Nottingham, U.K., is recruiting patients with relapsing-remitting multiple sclerosis (RRMS) to compare two treatment strategies, the National Multiple Sclerosis Society announced. The Phase 4 study, called DELIVER-MS (NCT03535298), intends to enroll about 800…

Cyxone submitted an application to the Netherlands research ethics committee to start the first clinical trial in humans testing T20K, its investigational preventive treatment for multiple sclerosis (MS). Approval by the Netherlands regulating authority…

MC10 and AbbVie are working together to launch clinical trials exploring the use of BioStamp nPoint, a system of wearable sensors that collects health data from multiple sclerosis (MS) patients, to determine if the information may serve as meaningful measures for clinical studies. MC10’s BioStamp…

The National Multiple Sclerosis Society has recently awarded $24.4 million in grants to support 64 research projects on multiple sclerosis (MS) worldwide, including $750,000 to fund 14 high-risk, high-reward pilot projects that will test new ideas and seek answers to new and relevant questions. According to a society…

Phase 3 Trial of ADS-5102 Recruiting Participants of All MS Types This medication is similar to Ampyra (dalfampridine) because its goal is to improve walking in those with MS. It sure would be nice if we had another medication approved that could do that. Though this trial began recruiting…

A Phase 3 trial testing ADS-5102 (amantadine) extended release capsules in all types of multiple sclerosis (MS) is enrolling participants to determine whether the oral therapy can improve walking speed. A total of 570 adults with MS, ages 18 to 70 years, who have difficulty walking will be…

The Cleveland Clinic Nevada is recruiting participants for DELIVER-MS, a clinical trial comparing two common treatment approaches for relapsing-remitting multiple sclerosis (RRMS). Results from the DELIVER-MS trial, titled “Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis” (…

Researchers at Kent and Canterbury Hospital, U.K., are recruiting 20 patients with multiple sclerosis (MS) who can walk at least eight meters with a walking aid to test the effectiveness of a five-week exercise program using assistive robotic technology. A patient completes balance and strengthening exercises using the…

A clinical trial to test the effects of antioxidant treatment with lipoic acid on progressive forms of multiple sclerosis (MS) is recruiting 118 participants at seven sites in North America. The study sites include: Birmingham, Alabama; Burlington, Vermont;  Portland, Oregon; Salt Lake City, Utah; Seattle, Washington; Washington, D.C., and;…

A clinical trial funded by the National Multiple Sclerosis Society is recruiting adult patients with multiple sclerosis (MS) to test two non-pharmacological strategies to manage MS-related chronic pain. The trial (NCT03782246) will be conducted at the University of Washington, and plans to enroll about 250 participants across…

WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity I’m one of the many people with multiple sclerosis (MS) for whom spasticity is a significant problem. This is a nonmedicinal approach to dealing with it. I hope it doesn’t take too long to make this…